Trust The Evidence-Based Performance of Pfizer Feline Vaccines.

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Antigen</th>
<th>Diluent</th>
<th>Package</th>
</tr>
</thead>
<tbody>
<tr>
<td>Felocell® 4</td>
<td>Rhinotracheitis-MLV, Calici-MLV, Panleukopenia-MLV, Chlamydia psittaci (Chlamyphila felis)-ML</td>
<td>Sterile Diluent</td>
<td>25 X 1-dose</td>
</tr>
<tr>
<td>Felocell® 3</td>
<td>Rhinotracheitis-MLV, Calici-MLV, Panleukopenia-MLV</td>
<td>Sterile Diluent</td>
<td>25 X 1-dose</td>
</tr>
<tr>
<td>Felocell® P</td>
<td>Panleukopenia-MLV</td>
<td>Sterile Diluent</td>
<td>25 X 1-dose</td>
</tr>
<tr>
<td>Felocell® FVR C (IN)</td>
<td>Rhinotracheitis-MLV, Calici-MLV</td>
<td>Sterile Diluent</td>
<td>25 X 1-dose</td>
</tr>
<tr>
<td>Leukocell® 2</td>
<td>Feline Leukemia-Killed Virus</td>
<td>None</td>
<td>50 X 1-dose</td>
</tr>
<tr>
<td>Felocell® FIP (IN) *</td>
<td>Feline Infectious Peritonitis-MLV</td>
<td>Sterile Diluent</td>
<td>25 X 1-dose</td>
</tr>
</tbody>
</table>

*Not covered by the Immunization Support Guarantee: Felocell FIP (IN)
Pfizer feline vaccines are backed by rigorous testing and most are backed by our immunization support guarantee, so you can vaccinate with the utmost confidence.

Pfizer was the first company to provide long-term vaccine serology data.¹

Pfizer led the discussion on vaccine duration of immunity.¹

Documented by Peer-Reviewed Data and Published in the Journal of the American Veterinary Medical Association¹

Unbiased Results: Serologic assays performed by prestigious outside laboratory (Cornell) blinded to the vaccination history of each animal

Demonstrated Performance: Felocell produced a consistent serologic response, often lasting up to and beyond 48 months for all 3 key antigens evaluated

Felocell: The feline vaccines with peer-reviewed, published and labeled serology data

**Pfizer Felocell® Feline Non-adjuvanted Upper Respiratory Vaccines**

Felocell 4, Felocell 3

<table>
<thead>
<tr>
<th>ANTIGENS</th>
<th>Felocell® 4</th>
<th>Felocell® 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feline Panleukopenia</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Feline Rhinotracheitis</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Feline Calicivirus</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td><em>Chlamydio psittaci</em> (<em>Chlamydophila felis</em>)</td>
<td>●</td>
<td>●</td>
</tr>
</tbody>
</table>

**Advantages**

- Modified Live Virus (MLV) that overrides maternal antibodies helps ensure a strong, rapid immune response.
- Felocell is a non-adjuvanted MLV vaccine, unlike commonly used killed vaccines.
- Contains highly immunogenic Johnson Snow Leopard feline panleukopenia virus (FPV) strain for reliable protection against FPV.
- No serious reactions in field trials involving 2,288 cats.
- Backed by peer-reviewed, published and labeled serology data.
Safety and Efficacy

Safety of Felocell 3 and 4 was demonstrated in field trials involving 2,288 cats. No serious post-vaccination reactions attributable to the vaccine were reported, however, approximately 1% of vaccinated cats with Felocell 4 exhibited lethargy, anorexia, and fever.

Efficacy of Felocell 3 and 4 was determined by challenge-of-immunity studies. Vaccinated cats experienced significantly less severe clinical signs than nonvaccinated control cats after challenge with virulent FVR virus, FCV, FPV or *Chlamydia psittaci*.

Efficacy of the FPV fraction in Felocell 3 was further established in a 3-year repeat antigenicity study. Three years after initial efficacy studies were conducted, FPV challenge tests were repeated. After challenge, all vaccinated cats remained clinically healthy while 80% of control cats developed clinical signs of feline panleukopenia (FPL).

Dosage and Administration

**General Directions:** Vaccination of healthy cats is recommended. Aseptically rehydrate the freeze-dried vaccine with the sterile diluent provided, shake well, and administer 1 mL intramuscularly or subcutaneously.

**Primary Vaccination:** Healthy cats 12 weeks of age or older should receive 2 doses administered 3 to 4 weeks apart. Cats vaccinated at less than 12 weeks of age should be revaccinated at 12 weeks of age.

**Revaccination:** Annual revaccination with a single dose is recommended, although, as recommended by the American Veterinary Medical Association and its Council on Biologic and Therapeutic Agents, the attending veterinarian should determine the frequency of revaccination based on the animal’s lifestyle and risk of exposure.¹

Pfizer Immunization Support Guarantee

Pfizer core vaccines may be used in extended duration protocols as recommended by the American Animal Hospital Association and the American Association of Feline Practitioners. In addition to providing immunization support for the full three years, Vanguard and Felocell are covered by an extra year of support because they provide long-term serologic performance demonstrated by four years of serology data. No other vaccines offer that level of support.

Precautions

Store at 2°C to 7°C. Prolonged exposure to higher temperatures and/or direct sunlight may adversely affect potency. Do not freeze. Use entire contents when first opened. Sterilized syringes and needles should be used to administer these vaccines. Do not sterilize with chemicals because traces of disinfectant may inactivate the vaccine. Burn containers and all unused contents.

Contains gentamicin as preservative.

As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine or equivalent is recommended and should be followed with appropriate supportive therapy.

This product has been shown to be efficacious in healthy animals. A protective immune response may not develop if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or if the vaccine is not administered according to label directions.

The use of Felocell 4 has been associated with fever, anorexia, and lethargy in 1% of vaccinated cats, often occurring in clusters in association with multiple concurrent vaccinations. Onset typically occurs 7 to 21 days after vaccination, with symptoms persisting for 3 to 30 days, with an average of 12 days. Veterinary intervention may be required. Treatment typically involves supportive care, steroids, and antibiotics.

Vaccination of pregnant queens should be avoided. For use in cats only.

In case of accidental human exposure, consult a physician.

Product Information

Customer-friendly packaging includes peel-off labels to make record-keeping faster and more accurate, a color-coded organizing system and an easy-open safety band.

25 x 1-dose vials

Product codes:

Felocell 4 - 4310
Felocell 3 - 4305
Pfizer Felocell® Protocol-Specific Feline Vaccines

Felocell P, Felocell FVR C (IN)

---

<table>
<thead>
<tr>
<th>ANTIGENS</th>
<th>Felocell® P</th>
<th>Felocell® FVR C (IN)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feline Panleukopenia</td>
<td>•</td>
<td>•</td>
</tr>
<tr>
<td>Feline Rhinotracheitis</td>
<td>•</td>
<td>•</td>
</tr>
<tr>
<td>Feline Calicivirus</td>
<td>•</td>
<td>•</td>
</tr>
</tbody>
</table>

Protocol-specific vaccines are administered more selectively than recommended core vaccines based on individualized medical decisions that take into account a risk/benefit ratio based on the cat’s geographic location, lifestyle and medical history.

✦ Advantages

• Highly specialized vaccines that allow for tailored protocols.

**Felocell P**
Felocell P contains the potent, demonstrated Johnson Snow Leopard strain of feline panleukopenia virus (FPV) for reliable protection against feline panleukopenia (FPL).

**Felocell FVR C (IN)**
Felocell FVR C contains attenuated strains of feline herpesvirus-1 (FHV-1) and feline calicivirus (FCV) propagated on established cell lines.
Safety and Efficacy

**Felocell P**
Safety of Felocell P was demonstrated in field trials involving 2,288 cats. No serious post-vaccination reactions attributable to the vaccine were reported.

Efficacy of Felocell P was determined by a challenge-of-immunity study. Vaccinated cats experienced significantly less severe clinical signs than nonvaccinated control cats after challenge with virulent FPV virus. In specific-pathogen-free cats, vaccination with Felocell P stimulated serologic titers to FPV.

**Felocell FVR C (IN)**
Safety of Felocell FVR C (IN) was evaluated. Clinical signs of disease or other adverse side effects attributable to vaccination were not observed in any test animals, including pregnant, susceptible cats, which delivered live, healthy litters.

Tests of serologic response to vaccination with Felocell FVR C (IN) indicated that no interference existed between the vaccine fractions. Even kittens vaccinated as early as 2 weeks of age developed protective FVR and FCV serum neutralization titers at 3 weeks post-vaccination.

In challenge-of-immunity tests, all cats vaccinated with Felocell FVR C (IN) remained clinically normal after challenge with virulent FCV or FVR virus. In contrast, all non-vaccinated control cats showed signs of disease after challenge.
Dosage and Administration

**Felocell P**

**General Directions:** Vaccination of healthy cats is recommended. Aseptically rehydrate the freeze-dried vaccine with the sterile diluent provided. Shake well. Administer 1 mL intramuscularly or subcutaneously.

**Primary Vaccination:** Healthy cats 12 weeks of age or older should receive 2 doses administered 3 to 4 weeks apart. Cats vaccinated at less than 12 weeks of age should be revaccinated at 12 weeks of age.

**Revaccination:** Annual revaccination with a single dose is recommended, although, as recommended by the American Veterinary Medical Association and its Council on Biologic and Therapeutic Agents, the attending veterinarian should determine the frequency of revaccination based on the animal’s lifestyle and risk of exposure.1

**Felocell FVR C (IN)**

**General Directions:** Vaccination of healthy cats is recommended. Aseptically rehydrate the freeze-dried vaccine with the sterile diluent provided. Shake well. Using the sterile dropper, inoculate nasal passages with entire volume of vaccine. Alternatively, 1 drop of vaccine may be placed into each eye and the remainder in the nasal passages. Administer vaccine within 30 minutes after rehydration.

**Primary Vaccination:** Healthy cats 12 weeks of age or older should receive one 0.5 mL dose. Cats vaccinated at less than 12 weeks of age should be revaccinated at 12 weeks of age.

**Revaccination:** Annual revaccination with a single dose is recommended.

Precautions

Store at 2°C to 7°C. Prolonged exposure to higher temperatures and/or direct sunlight may adversely affect potency. Do not freeze. Use entire contents when first opened. Burn containers and all unused contents. Contains gentamicin as preservative.

As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine or equivalent is recommended and should be followed with appropriate supportive therapy.

This product has been shown to be efficacious in healthy animals. A protective immune response may not develop if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or if the vaccine is not administered according to label directions.

**Felocell P:** Sterilized syringes and needles should be used to administer Felocell P. Do not sterilize with chemicals because traces of disinfectant may inactivate the vaccine. Vaccination of pregnant queens should be avoided.

**Felocell FVR C (IN):**

**Warning:** For intranasal use in cats only. Transient sneezing may be observed 4 to 7 days after vaccination. Oral lesions may be observed after vaccination, but typically heal without complications. Vaccination of cats incubating or harboring latent infections may result in more pronounced upper respiratory signs, ocular irritation, or febrile response.

---

Product Information

Customer-friendly packaging includes peel-off labels to make record-keeping faster and more accurate, a color-coded organizing system and an easy-open safety band.

25 x 1-dose vials

Product codes:
Felocell P - 5312
Felocell FVR C (IN) - 4350
Pfizer Leukocell® 2 Vaccine

**Advantages**

- Demonstrated efficacy in helping prevent persistent viremia, lymphoid tumors caused by feline leukemia virus (FeLV), and FeLV-associated diseases.
- The only FeLV vaccine with the tumor-specific antigen FOCMA and demonstrated FeLV tumor protection.
- Prepared from an FeLV-transformed lymphoid cell line that releases soluble FeLV particles into cell culture medium, reducing the immunosuppressive effects of fully assembled, inactivated or live FeLV.
- More than 50 million doses of Leukocell vaccines sold.

**Safety and Efficacy**

In an immunogenicity study, 25 specific pathogen free (SPF) cats were vaccinated with a 2-dose primary regimen (2 doses were given 3 weeks apart). After the second dose, significant levels of antibodies to gp70 and FOCMA were detected as well as virus neutralizing (VN) antibodies.

Rigorous safety tests of Leukocell 2 did not demonstrate any immunosuppressive effects. Kittens vaccinated with Leukocell 2 had normal post-vaccination white blood cell (WBC) counts, did not become viremic, remained clinically normal, and developed gp70, FOCMA, and VN antibodies.

Post-vaccination reactions have been observed in about 2% of vaccinated cats. These included stinging on injection, transient listlessness, depression, and brief temperature elevations. Hypersensitivity evidenced by myxedema and gastrointestinal distress (vomiting and bowel evacuation) occasionally has been reported.

After challenge with the Rickard strain of FeLV, which infected 100% of the control cats, more than 70% of the vaccinates were protected against establishment of persistent viremia. In contrast, 60% of nonvaccinated control cats developed persistent viremia.

**Dosage and Administration**

**General Directions:** Shake well and administer 1 mL subcutaneously.

**Primary Vaccination:** Healthy cats 9 weeks of age or older should receive 2 SC doses administered 3 to 4 weeks apart.

**Revaccination:** Annual revaccination with a single dose is recommended.
Pfizer Leukocell® 2 Vaccine (continued)

❖ Precautions

Although a diagnostic test for FeLV antigen is not required prior to vaccination with Leukocell 2, such a test may be beneficial in evaluating candidates for vaccination. Vaccination is of no known therapeutic value in cats with existing FeLV infection, nor will it alter the natural course of disease.

Store at 2°C to 7°C. Prolonged exposure to higher temperatures may adversely affect potency. Do not freeze. Use entire contents when first opened. Sterilized syringes and needles should be used to administer this vaccine. Contains gentamicin as preservative.

As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.

This product has been shown to be efficacious in healthy animals. A protective immune response may not develop if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or if the vaccine is not administered according to label directions.

❖ Product Information

Customer-friendly packaging includes peel-off labels to make record-keeping faster and more accurate, a color-coded organizing system and an easy-open safety band.

50 x 1-dose vials

Product code:
Leukocell 2 - 4363
Advantages

- Cats vaccinated intranasally (IN) with Felocell FIP developed a protective immune response and did not become hypersensitized. This practical benefit may be attributed to the temperature-sensitive Felocell FIP vaccine strain, which replicates in the upper respiratory tract, but does not spread systemically at 39°C, the cat’s body temperature.
- Felocell FIP is the only commercial vaccine that aids in the prevention of FIP, a disease associated with a high incidence of mortality.

Safety and Efficacy

In safety tests, Felocell FIP did not cause illness in cats when administered intranasally. It did not cause illness in cats infected with feline leukemia, in cats exposed to feline enteric coronavirus, in dexamethasone-immunosuppressed cats, in nonvaccinated cats that survived FIP challenge, or in kittens.

Felocell FIP did not interfere with the development of an antibody response to any of the following feline vaccine antigens: feline leukemia virus, feline rhinotracheitis virus, feline calicivirus, feline panleukopenia virus, and Chlamydia psittaci (Chlamydophila felis). Conversely, none of these vaccine antigens interfered with the immunogenicity of Felocell FIP.

In an immunogenicity study, 20 seronegative cats were vaccinated with a 2-dose primary regimen (given 3 weeks apart). All vaccinates developed feline infectious peritonitis (FIP) virus antibody titers, and 17 of the 20 (85%) survived an FIP virus challenge that caused FIP in 12 of 12 (100%) nonvaccinated controls. Ten of the 12 controls died. Sixteen of the 17 (94%) vaccinated cats that survived the first challenge survived a second challenge, which caused FIP in 4 of 6 nonvaccinated controls.

In a second immunogenicity study, 20 of 20 seronegative cats developed FIP virus antibody titers after primary vaccination with 2 doses given 3 weeks apart. Fifteen of 20 (75%) vaccinates were protected against a challenge of immunity in which 7 of 10 (70%) nonvaccinated control cats died of FIP. All but 1 of the surviving vaccinated cats from the first challenge survived a second challenge, which killed 6 of 6 nonvaccinated controls.

In addition to protecting against homologous challenge, Felocell FIP also protected cats against a heterologous challenge strain (WSU-1146). Clinical FIP symptoms of vaccinated cats were significantly lower (P<0.05) than symptoms of control cats following WSU-1146 challenge. Eight of 10 (80%) vaccinated cats survived a challenge of immunity with the WSU-1146 strain of FIP in which 3 of 5 (60%) non-vaccinated controls died of FIP.
Dosage and Administration

**General Directions:** Vaccination of healthy cats is recommended. Aseptically rehydrate the freeze-dried vaccine with the sterile diluent provided. Mix well. Use dropper to inoculate entire volume into nasal passages, one-half the volume into each nasal passage. Cats may sneeze or shake their heads at the time of administration.

**Primary Vaccination:** Healthy cats 16 weeks of age or older should receive 2 IN doses administered 3 to 4 weeks apart.

**Revaccination:** Annual revaccination with a single dose is recommended.

Precautions

Store at 2°C to 7°C. Prolonged exposure to higher temperatures and/or direct sunlight may adversely affect potency. Do not freeze. Use entire contents when first opened. Burn containers and all unused contents. Contains gentamicin as preservative. Droppers should be used to administer this vaccine.

As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.

This product has been shown to be efficacious in healthy animals. A protective immune response may not develop if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or if the vaccine is not administered according to label directions.

For use in cats only.

Product Information

Customer-friendly packaging includes peel-off labels to make record-keeping faster and more accurate, a color-coded organizing system and an easy-open safety band.

25 x 1-dose vials

**Product code:**
Felocell FIP(IN) - 4643
**Advantages**

- Contains a highly immunogenic, fixed strain of rabies virus that originated from Louis Pasteur’s original 1882 isolate.
- Vaccine formulated with a chemically inactivated rabies virus prepared from cell culture.
- Exceptionally well tolerated after injection due to the purified adjuvant and a novel dual-buffering system that restricts pH to a narrow, safe range.
- Defensor vaccines produced for sale in California meet specific potency standards required by that state.

**Safety and Efficacy**

Studies conducted in mice to evaluate the relative effective dose of Defensor 3 vs a Centers for Disease Control and Prevention (CDC) referenced virus against 5 wild rabies viruses indicated that vaccine effectiveness extends beyond canine isolates to include naturally occurring wildlife strains with exceptional protection against raccoon and bat rabies viruses.\(^1\)

Because Defensor is produced on an established cell line, it has safety advantages over inactivated brain-origin rabies vaccines. Tissue-origin vaccines contain extraneous protein in addition to rabies antigen that can lead to autoimmune disease.

The established cell line used in Defensor has been extensively tested for freedom from contaminating agents. In addition, use of an established cell line yields a vaccine of consistent potency from serial to serial. Defensor has been demonstrated to be uniformly safe in experimental tests, and no significant adverse reactions were reported in extensive clinical trials of the vaccine.

A duration-of-immunity study, conducted in accordance with federal regulation and under US Department of Agriculture (USDA) direction, demonstrated that a 1 mL dose of Defensor 3 met federal guidelines for protection of dogs and cats against virulent challenge administered 3 years after vaccination.

In a field safety study, with 2,647 doses administered, 96.2% of the doses were administered with no vocalization and 99.9% of doses were administered with no lameness, stiffness, hypersensitivity reactions, or injection site lumps for 21 days after vaccination.\(^2\)

**Dosage and Administration**

**General Directions:** Shake well. Aseptically administer 1 mL subcutaneously for cats. Dogs may be vaccinated intramuscularly or subcutaneously.

**Primary Vaccination:** Administer a single 1 mL dose at 3 months of age or older to healthy dogs and cats. A repeat dose should be given 1 year later.

**Revaccination:**
**Defensor 1:** Annual revaccination with a single dose is recommended.
**Defensor 3:** Subsequent revaccination every 3 years with a single dose is recommended.

---

Precautions

Store at 2°C to 7°C. Prolonged exposure to higher temperatures may adversely affect potency. Do not freeze. Use entire contents when first opened. Sterilized syringes and needles should be used to administer this vaccine. Contains gentamicin as preservative.

As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.

Defensor has been shown to be efficacious in healthy animals. A protective immune response may not develop if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or if the vaccine is not administered according to label directions.

Product Information

Customer-friendly packaging includes peel-off labels to make record-keeping faster and more accurate, a color-coded organizing system and an easy-open safety band.

5 x 10-dose vials
50 x 1-dose vials

Product codes:
Defensor 1 (50 x 1-dose) - 4985
Defensor 1 (5 x 10-dose) - 4654
Defensor 3 (50 x 1-dose) - 4996
Defensor 3 (5 x 10-dose) - 4997
Defensor 3 (Calif 50 x 1-dose) - 4627
Defensor 3 (Calif 5 x 10-dose) - 4628
Insist on Quality Without Compromise.

✦ Evidence-Based Science.
In the lab and in the field, our vaccine products continue to demonstrate their efficacy and safety year after year.

✦ Peer-Reviewed and Published Research.
Pfizer vaccines are tested under a variety of conditions in large scale, multicenter studies. Whenever possible, this data is then peer-reviewed and published, so you can vaccinate with confidence.

✦ Confidence Based in Science. Peace of Mind with Unequaled Support.
We are so confident in our products that we offer an unprecedented 4-year support guarantee on our core vaccines, as well as a 1-year guarantee on other Pfizer vaccines.

www.ISG.com for additional information